Cellectis (CLLS) Stock Price, News & Analysis

Company Overview

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies. Its pipeline includes multiple CAR‐T candidates, such as those targeting CD19 and CD22 antigens for B‐cell malignancies and other programs addressing acute myeloid leukemia. Cellectis advances these investigational therapies through preclinical research and early‐ to mid‐stage clinical trials, often in partnership with leading pharmaceutical firms to enhance development and commercialization capabilities.

Cellectis operates research and process development laboratories as well as GMP manufacturing facilities across Europe and North America. Clinical trials are conducted in premier cancer centers in the United States and Europe, reflecting the company’s global reach. Strategic collaborations and licensing agreements support the expansion of its gene‐edited therapies into new indications and geographic markets, with an emphasis on scalable production and regulatory readiness.

Under the leadership of founder and Chief Executive Officer Dr. André Choulika, Cellectis has established itself as a pioneer in TALEN‐based genome editing. The management team combines scientific and commercial expertise to drive innovation, with a focus on delivering next‐generation allogeneic CAR‐T therapies to patients worldwide.

Key Stats

• Today's Range: $3.10 to $3.50
• 50-Day Range: $2.60 to $3.56
• 52-Week Range: $2.35 to $5.48
• Volume: 9,822 shs
• Average Volume: 20,119 shs
• Market Capitalization: $331.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Cellectis Stock Analysis - MarketRank™

Cellectis scored higher than 39% of companies evaluated by MarketBeat, and ranked 709th out of 916 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cellectis has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cellectis has a consensus price target of $7.00, representing about 112.1% upside from its current price of $3.30.

Amount of Analyst Coverage

Cellectis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cellectis is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cellectis is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cellectis has a P/B Ratio of 8.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.36% of the float of Cellectis has been sold short.

Short Interest Ratio / Days to Cover

Cellectis has a short interest ratio ("days to cover") of 14.18, which indicates bearish sentiment.

Change versus previous month

Short interest in Cellectis has recently increased by 1.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cellectis does not currently pay a dividend.

Dividend Growth

Cellectis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.75

News Sentiment

Cellectis has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cellectis this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Cellectis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cellectis insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/01/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CLLS
• CIK: 1627281
• Web: www.cellectis.com
• Phone: (318) 169-1600
• Fax: 33-1-81-69-16-06
• Employees: 290
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cellectis: $7.00
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +112.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.59 million
• Net Margins: -102.34%
• Pretax Margin: -102.89%
• Return on Equity: -94.19%
• Return on Assets: -21.34%

Debt

• Debt-to-Equity Ratio: 1.61
• Current Ratio: 1.37
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $56.58 million
• Price / Sales: 5.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: 8.05

Miscellaneous

• Outstanding Shares: 100,339,000
• Free Float: 83,873,000
• Market Cap: $331.12 million
• Optionable: Optionable
• Beta: 2.91